FIELD: biotechnology.
SUBSTANCE: described is a group of inventions comprising a pharmaceutical composition for treating a disease or disorder that can be cured by GDF8 activity (embodiments) inhibition, and use of said pharmaceutical composition for preparing a drug for treating a patient suffering a disease or disorder that can be cured by inhibiting GDF8 activity, diagnosing said disease or disorder or treating a patient at risk of developing such a disease or disorder. In one embodiment, the pharmaceutical composition contains an effective amount of an isolated human antibody or antigen-binding fragment thereof, which specifically binds or blocks the biological activity of the mature wild-type human GDF8 protein comprising the sequence SEQ ID NO: 340.
EFFECT: invention extends the range of agents for treating a disease or disorder that can be cured by inhibiting GDF8 activity.
14 cl, 6 dwg, 27 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST HUMAN GDF8 | 2011 |
|
RU2567805C2 |
| COMPOSITIONS AND METHODS FOR INCREASING BODY WEIGHT AND LEAN MUSCLE MASS USING LEPTIN RECEPTOR ANTAGONISTS, GDF8 AND ACTIVIN A | 2019 |
|
RU2818832C2 |
| HUMAN ANTIBODIES TO Fel d1 AND METHODS OF USE THEREOF | 2013 |
|
RU2658491C2 |
| ANTI-ANGPTL3 ANTIBODIES AND THEIR APPLICATION | 2012 |
|
RU2620064C2 |
| MONOCLONAL ANTIBODY ABLE TO BIND TO SPECIFIC DISCONTINUOUS EPITOPE PLACED IN AD1 REGION OF HUMAN CYTOMEGALOVIRUS GB GLYCOPROTEIN, AND ITS ANTIGEN-BINDING FRAGMENT | 2010 |
|
RU2542472C2 |
| HUMAN RET-BINDING ANTIBODIES AND METHODS OF USE THEREOF | 2020 |
|
RU2821548C2 |
| HUMANIZED TAU-ANTIBODY | 2013 |
|
RU2644242C2 |
| METHOD OF TREATING CANCER WITH DLL4 ANTAGONIST AND CHEMOTHERAPEUTIC AGENT | 2010 |
|
RU2571220C2 |
| APPLICATION OF ANTIBODY AGAINST AMYLOID-BETA IN CASE OF EYE DISEASES | 2008 |
|
RU2571859C2 |
| ANTIBODIES OF HIGH AFFINITY TO IL-6-RECEPTOR OF HUMANS | 2007 |
|
RU2433138C2 |
